HIGHMARK .

Member Name:	DOB:			
Member ID (UMI):	Medicare Commercial			
Address:				
ORDERING/ATTENDING PROVIDER				
Physician Name:	NPI:			
Address:				
Office Contact: Phone	e Number:Fax Number:			
SITE OF CARE				
Place of Service (please select one)				
□ Home Infusion □ Office – Professional □ Ar	nbulatory Infusion Suite – Professional 🛛 🗆 Outpatient Hospital			
Is the site of care affiliated with a hospital or w	ill the claim be billed as a facility claim? \Box Yes \Box No			
Place of Service Name:	NPI:Tax ID:			
Address:				
Phone Number:	Fax Number:			
Drug Supplier (please select one)				
□ Supplied by a Specialty Pharmacy (for Home Infus	sion, Office – Professional, or Ambulatory Infusion Suite – Professional)			
Pharmacy Name:	Pharmacy NPI:			
□ Buy & Bill (for Office – Professional or Outpatient	Hospital administration)			
DRUG INFORMATION (please select one)				
PREFERRED for ALL indications	NON-PREFERRED**			
Avsola Q5121	Remicade J1745			
Inflectra Q5103	Has the member experienced a documented drug therapy failure or intolerance to the <u>preferred products?</u>			
	Avsola: 🛛 Yes 🗍 No			
	Inflectra: 🛛 Yes 🗍 No			
** <u>Medicare members</u> currently established on a non-preferred therapy are not required to try a preferred option	** A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial, or intolerance, or contraindication to BOTH preferred products			

Please verify member's eligibility and benefits through the health plan

Strength or Dose:Date(s) of service:		
Qı	antity (# of doses/visits):	
Member weight:		
Non-infectious Uveitis	Juvenile Rheumatoid Arthritis (JRA/JIA)	
Ulcerative Colitis (UC)	Psoriatic Arthritis (PsA)	
Infliximab being used in combination NO, please explain:	n with Methotrexate?	
	Qu M Non-infectious Uveitis Ulcerative Colitis (UC)	

Door the	mombor	have	moderate	+~	covoro	dicaaca2	
Does the	member	nave	moderate	ιο	severe	uiseaser	

List all previous therapies tried and failed ______

New Start	Continuation of Therapy		
	Date of last infusion:		
	Has the member demonstrated disease stability or a beneficial response to therapy?		

Please attach all pertinent clinical information	
Attached:	

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.